NLRP3 and atrial fibrillation: Furthermore, Wu et al. [120] investigated the role of the NLRP3 inflammasome-CASP1-galectin 3 pathway in AF and atrial remodeling, and evaluated the effects of glibenclamide, a hypoglycemic agent and NLRP3 inflammasome inhibitor, in diabetic rabbits.